Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous syst... Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous system disorders. The company focuses on conditions with limited treatment options, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome's approach includes fixed-dose combinations and reformulations designed to deliver differentiated therapeutic solutions. The company maintains a pipeline of clinical-stage CNS therapies addressing significant and growing markets. Founded in 2012 and headquartered in New York, New York, Axsome operates as a single business segment dedicated to developing and delivering innovative treatments for patients with underserved CNS conditions. The company has transitioned to commercializing its marketed products while advancing its pipeline of differentiated therapeutic candidates.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Greenhouse Gas (GHG) Emissions data disclosed by Axsome Therapeutics

We reviewed Axsome Therapeutics's website and available disclosure materials for the 2024 reporting period and did not identify any reported Greenhouse Gas (GHG) Emissions data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Axsome Therapeutics's data?

Start your 30-day free trial to request a data review for Axsome Therapeutics.

Start Free Trial

Legal Center Contact Us

Axsome Therapeutics Inc

No Greenhouse Gas (GHG) Emissions data disclosed by Axsome Therapeutics

Account Restricted